<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377699</url>
  </required_header>
  <id_info>
    <org_study_id>NN1250-4300</org_study_id>
    <secondary_id>U1111-1191-3018</secondary_id>
    <secondary_id>2017-000048-17</secondary_id>
    <nct_id>NCT03377699</nct_id>
  </id_info>
  <brief_title>Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes</brief_title>
  <acronym>EXPECT</acronym>
  <official_title>A Trial Comparing the Effect and Safety of Insulin Degludec Versus Insulin Detemir, Both in Combination With Insulin Aspart, in the Treatment of Pregnant Women With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are doing this study to see the effect of insulin degludec in pregnant
      women with type 1 diabetes, and if it is safe to use. In this study the medicine insulin
      degludec is compared to another medicine called insulin detemir. Participants will either get
      insulin degludec or insulin detemir and take it together with a medicine called insulin
      aspart - which treatment participants get is decided by chance. Participants will get
      pre-filled insulin pens. Participants will need to take blood sugar measurements several
      times a day. The study will last between 10 and 25 months depending on whether participants
      are already pregnant when they join the study. The number of visits and the tests ( for
      example blood and urine samples and ultrasound scans) the participants will have also depends
      on whether they are pregnant at study start.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 22, 2017</start_date>
  <completion_date type="Anticipated">April 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 14, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Sponsor staff involved in the clinical trial is masked according to company standard procedures.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Last planned glycosylated haemoglobin (HbA1c) prior to delivery</measure>
    <time_frame>After gestational week 16 to last planned measurement at gestational week 36 plus 7 days</time_frame>
    <description>Measured in %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c below or equal to 6.0% (42 mmol/mol) from last planned HbA1c prior to delivery (yes/no)</measure>
    <time_frame>After gestational week 16 to last planned measurement prior to delivery</time_frame>
    <description>Proportion of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last planned average post-prandial glucose prior to delivery. Average of three main meals.</measure>
    <time_frame>After gestational week 16 to last planned measurement prior to delivery</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last planned fasting plasma glucose prior to delivery</measure>
    <time_frame>After gestational week 16 to last planned measurement prior to delivery</time_frame>
    <description>Measured in mg/dl or other equivalent SI units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycaemic episodes</measure>
    <time_frame>During the pregnancy period (from first day of pregnancy (date of conception) or randomisation (whichever comes last) to delivery)</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of sight-threatening retinopathy defined as proliferative retinopathy or maculopathy (yes/no)</measure>
    <time_frame>From treatment baseline (visit 2, week0), to end of treatment visit after delivery (up to 28 days after delivery)</time_frame>
    <description>Proportion of subjects with events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>During the pregnancy period (from first day of pregnancy (date of conception) or randomisation (whichever comes last) to delivery)</time_frame>
    <description>Count and % of Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-eclampsia defined as new-onset hypertension occurring from gestational week 20 to delivery and simultaneous proteinuria or presence of eclampsia, HELLP syndrome, or other severe organ involvement (yes/no)</measure>
    <time_frame>Occurring from gestational week 20 to delivery</time_frame>
    <description>Number of combined events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight (kg)</measure>
    <time_frame>At birth</time_frame>
    <description>Measured in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-term delivery (delivery before 37 completed gestational weeks) (yes/no)</measure>
    <time_frame>At birth</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of major abnormalities (classified according to EUROCAT) (yes/no)</measure>
    <time_frame>At birth</time_frame>
    <description>Number of children with abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live born infants (yes/no)</measure>
    <time_frame>At birth</time_frame>
    <description>Number of children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events in the infant</measure>
    <time_frame>From delivery to final follow-up 30 days after delivery</time_frame>
    <description>Count and % of Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal hypoglycaemic episodes defined as plasma glucose below or equal to 1.7 mmol/L (31 mg/dL) or below or equal to 2.5 mmol/L (45 mg/dl) (yes/no)</measure>
    <time_frame>During the first 24 hours after birth</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c below or equal to 6.5% (48 mmol/mol) from last planned HbA1c prior to delivery (yes/no)</measure>
    <time_frame>After gestational week 16 to last planned</time_frame>
    <description>Proportion of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mode of delivery, e.g. vaginal, operative vaginal, planned caesarean section or unplanned caesarean section, induced or spontaneous delivery</measure>
    <time_frame>At birth</time_frame>
    <description>Number of type of delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>From pregnancy baseline (corresponding to gestational week 8-13) to last planned visit before delivery (last weight recording before given birth)</time_frame>
    <description>Measured in kg and/or %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early foetal death (delivery before 20 completed GWs) (yes/no)</measure>
    <time_frame>At birth</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal mortality (death of foetus/infant ) (yes/no)</measure>
    <time_frame>Between at least 20 completed GWs before delivery and before 7completed days after delivery</time_frame>
    <description>Number of children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mortality (death of infant) (yes/no)</measure>
    <time_frame>Between at least 7 completed days after delivery and before 28 completed days after delivery</time_frame>
    <description>Number of children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of sight-threatening retinopathy defined as proliferative retinopathy or maculopathy (yes/no)</measure>
    <time_frame>From pregnancy baseline (corresponding to gestational week 8-13) to end of treatment visit after delivery (up to 28 days after delivery)</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal hypoglycaemic episodes defined as plasma glucose below or equal to 1.7 mmol/L (31 mg/dL) or below or equal to 2.5 mmol/L (45 mg/dl) (yes/no)</measure>
    <time_frame>During between 24 and 48 hours after birth</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Insulin Degludec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Degludec once daily and Insulin Aspart 2-4 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Determir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Determir once daily or twice daily and Insulin Aspart 2-4 times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin degludec</intervention_name>
    <description>Injection for subcutaneous (s.c., under the skin) use once daily. The total trial duration for subjects will be maximum 25 months</description>
    <arm_group_label>Insulin Degludec</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>Injection for subcutaneous (s.c., under the skin) use 2-4 times daily with meals.
The total trial duration for subjects will be maximum 25 months</description>
    <arm_group_label>Insulin Degludec</arm_group_label>
    <arm_group_label>Insulin Determir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin detemir</intervention_name>
    <description>Injection for subcutaneous (s.c., under the skin) use, once daily or twice daily.
The total trial duration for subjects will be maximum 25 months</description>
    <arm_group_label>Insulin Determir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, age at least 18 years at the time of signing informed consent

          -  Diagnosed with type 1 diabetes mellitus for at least 1 year prior to the day of
             screening

          -  Treated with multiple daily subcutaneous insulin injections or continuous subcutaneous
             insulin infusion (CSII) or inhaled insulin for at least 90 days prior to the day of
             screening

          -  The subject is planning to become pregnant within 12 months from randomisation and
             willing to undertake pre-pregnancy counselling or the subject is pregnant with an
             intrauterine singleton living foetus (gestational week 8 to 13 (+6 days)) without any
             observed anomalies at randomisation, confirmed by an ultrasound scan

          -  HbA1c at screening below or equal to 8.0% (64 mmol/mol) by central laboratory

        Exclusion Criteria:

          -  Treatment with any medication for the indication of diabetes or obesity other than
             stated in the inclusion criteria within the past 90 days prior to the day of screening

          -  Pregnant and having proteinuria as evaluated by urine protein-to-creatinine ratio
             above or equal to 300 mg/g in urine sample measured at screening

          -  Subject being treated or became pregnant with assistance of in vitro fertilisation or
             other medical infertility treatment

          -  Receipt of any concomitant medication contraindicated in pregnancy according to local
             label within 28 days before screening and between screening and randomisation for
             non-pregnant subjects and 28 days before conception and between conception and
             randomisation for pregnant subjects

          -  Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus
             photography or pharmacologically dilated fundoscopy performed within the past 90 days
             prior to randomisation for non-pregnant subjects or within 28 days prior to
             randomisation for pregnant subjects.

          -  History of severe hyperemesis gravidarum (requiring hospitalisation)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Caba</city>
        <zip>C1180AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ipswich</city>
        <state>Queensland</state>
        <zip>4305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>A 1170</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <state>Goias</state>
        <zip>74605-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 7L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St John's</city>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>København ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>GR-11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Larissa</city>
        <zip>GR-41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR-56403</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin 2</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 7</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Galway</city>
        <zip>H91 YR71</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sant'Andrea Delle Fratte (PG)</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kirov</city>
        <zip>610014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>101000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>199034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ulianovsk</city>
        <zip>432063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yoshkar-Ola</city>
        <zip>424004</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>High Wycombe</city>
        <zip>HP11 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

